Thrombin Receptor Agonist 凝血酶受体兴奋剂
adrenergic receptor agonist 肾上腺素能受体增效剂
Adenosine A2 receptor agonist 腺苷A2受体激动剂
da receptor agonist da受体激动剂
M3 receptor agonist M3受体激动剂
nmda receptor agonist nmda受体激动剂
M1 receptor agonist M1受体激动剂
kappa receptor agonist kappa受体激动剂
BYETTA is the first FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes.
百泌达是FDA批准的治疗2型糖尿病的首个GLP - 1受体激动剂药物。
BYDUREON and BYETTA belong to the glucagon-like peptide-1 (GLP-1) receptor agonist class of medications.
BYDUREON和百泌达(BYETTA)都属于胰高血糖素样肽(GLP - 1)受体激动剂类药物。
Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist.
本文提供了反转或阻止靶细胞对死亡受体激动剂的抗性的方法。
应用推荐